Dr. Ghobrial is a Professor of Medicine and Senior Physician at Dana-Farber Cancer Institute, Harvard Medical School. She is also the Senior Vice President for Experimental Medicine, Lavine Family Chair for Preventative Cancer Therapies, Director of the Center for Early Detection and Interception of Blood Cancers, Co-Leader of the Lymphoma/Myeloma Cancer Center Program, and Director of the Ghobrial Lab at the Dana Farber Cancer Institute.

Dr. Ghobrial earned her medical degree from Cairo University School of Medicine, Egypt. She completed her residency in Internal Medicine at Wayne State University, Michigan, and Hematology/Oncology Fellowship at the Mayo Clinic College of Medicine, Minnesota, before joining Dana-Farber in 2004.

Her research focuses on precursor conditions of multiple myeloma, aiming to understand genetic, epigenetic, and immune mechanisms of disease progression, identify novel biomarkers, and develop therapies to eliminate disease before progression. She has led 15+ clinical trials in Waldenstrom macroglobulinemia and multiple myeloma precursor conditions. She developed the PCROWD Study, a large, patient-empowering observational study for these precursor conditions, and the PROMISE Study, which screens high-risk individuals, including those of African descent or with a family history of blood cancer.

She has authored over 300 articles and book chapters and has received funding support from the National Cancer Institute and foundations, including Stand Up To Cancer, the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, and the International Myeloma Foundation. Her career-long contributions to translational research have been recognized with the William Dameshek Prize from the American Society of Hematology, the National Cancer Institute Outstanding Investigator Award, and the Jan Gosta Waldenstrom Award from the International Workshop on Waldenstrom’s Macroglobulinemia.